Welcome to Dublin

DEAR COLLEAGUES AND FRIENDS, I look forward to welcoming you shortly to the 53rd Annual Meeting of ESPE in Dublin, Ireland, on 18–20 September.

Thank you for your abstracts. We are delighted that the number submitted has exceeded previous years, as has the number of people who have already registered. An interesting and exciting programme is planned, including internationally renowned experts speaking on the theme of ‘Prevention and therapeutic innovations in paediatric endocrinology’. Leading research in endocrinology will cover many topics, such as obesity, diabetes, sex determination and development, bone disorders, cancer syndromes, growth, puberty, thyroid disorders, gene therapy, new technologies, microRNAs in health and disease and the latest developments in regenerative endocrinology.

The ESPE 2014 Meeting will provide an international forum for the exchange of the latest basic scientific and clinical information, whilst promoting collaboration between clinicians, scientists, psychologists, nurses and health professionals from around the world. Delegates will enjoy prestigious plenary lectures, symposia, working groups, meet the expert and new perspective sessions and yearbook events. Interaction and discussion will be the essence of this meeting, with the free oral communications and poster sessions enabling all participants to benefit from leading expertise.

The meeting takes places in the new Convention Centre in the heart of Dublin, close to Trinity College and the Royal College of Physicians of Ireland, home to many medical scholars including Robert Graves, Dominic Corrigan, John Cheyne, William Stokes and Robert Adams.

Dublin is a city of ancient scholarship with a wealth of history, culture and architecture. Topping many lists of must-see destinations, the city boasts wide Georgian streets, mansions, squares, cathedrals and gardens, along with magnificent art galleries and museums (many with medical associations). Dublin is also home to a great literary tradition, boasting four Nobel Prize winners during the last century: WB Yeats, Samuel Beckett, George Bernard Shaw and Seamus Heaney. As the current European City of Science, a UNESCO City of Literature and former European City of Culture, this fantastic city will provide the perfect backdrop for the ESPE 2014 Meeting.

The meeting has an emphasis on interaction and informality, to promote opportunities to develop international collaboration in research and clinical practice, as well as to renew old friendships and make new friends.

We have an excellent scientific programme, but it is your participation that will make this meeting a success, and so I extend my warmest invitation to you to come to Dublin, and please encourage your senior and junior faculty colleagues and team members to join you.

Professor Hilary Hoey, hilaryhoey@eircom.net
President, ESPE 2014
There is much news about other ESPE activities, including the very successful 1st ESPE Diabetes and Obesity School (below) and the ESPE Visiting Scholarship programme (page 7). We are delighted to include an update on the Consensus Group on Rickets led by the ESPE Bone and Growth Plate Working Group (page 3). Experts from around the world have developed evidence-based guidelines on the prevention and management of nutritional rickets, a global problem.

Page 3 also features a progress report from the Accreditation and Syllabus Subcommittee on the revised ESPE Training Programme.

This issue’s interview is with Jan Lebl, a senior member. On page 6 you can discover what ESPE has brought to his academic life. We also thank Gary Butler for his review of a recently published book on auxology by Michael Hermanussen, which will evoke interest among our members. You can read his review on page 7.

We, as your Editorial Board, will do our best to continue to maintain the quality of the Newsletter and try to enrich it with feedback from all members. As always, I thank my colleagues in the Newsletter team for their support. We are pleased to welcome our new member, Abel López-Bermejo from Spain, to the Editorial Board of the Newsletter.

Yours sincerely,
Professor Feyza Darendeliler
Editor, ESPE Newsletter
feyzad@istanbul.edu.tr

We are already halfway through the year, and so many great ESPE programmes and activities have taken place: the ESPE Winter School, the ESPE Diabetes/Obesity School, the Consensus Conference on the Prevention and Management of Rickets and the Advanced Seminar in Developmental Endocrinology. The ESPE Research Fellowships and two Visiting Scholarships have also already been awarded. To keep up-to-date with all of ESPE’s programmes and activities, including information on how to apply and deadline dates, please visit our website which is updated regularly with the latest information.

The second half of the year promises to be just as busy, with two new schools taking place: the Caucasus & Central Asia School, Almaty, Kazakhstan in October and the ESPE/ASPED School, Abu Dhabi, UAE, in November. The Maghreb Project also takes place in Morocco in November and, of course, ESPE 2014 is in Dublin, Ireland, on 18–20 September.

ESPE 2014 promises to be another excellent scientific and networking occasion for your diary. Please do come and visit us at ESPE Connect, stand 1, where we would love to meet you and answer any questions or feedback you have about your Society. You can expect to find information about membership and ESPE’s programmes and activities, and there will be plenty of seats to rest your weary feet! Come and meet your colleagues and the ESPE team.

Please don’t forget to encourage your colleagues to join ESPE, with so many fantastic opportunities and membership categories to suit all medical professionals working in paediatric endocrinology. You can contact us via espe@eurospe.org, or find us on Facebook and Twitter if you have any queries. We look forward to meeting you in Dublin!

Hannah Bonnell, Joanne Fox-Evans, Tracey-Leigh Meadowcroft
ESPE Team
Consensus recommendations on rickets

RICKETS, HYPOCALCAEMIC SEIZURES and cardiomyopathy are common in countries with poor primary healthcare standards. These conditions have been successfully eradicated in most developed countries by adherence to universal vitamin D supplementation for infants.

The Consensus Conference on Prevention and Management of Rickets took place on 29–31 May 2014, in Birmingham, UK, with the aim of establishing global consensus recommendations on prevention and management of nutritional rickets.

Wolfgang Högler, Chairman of the ESPE Bone and Growth Plate Working Group, brought together 33 experts from around the world to develop evidence-based guidelines. The consensus conference was endorsed by ESPE, PES, SLEP, JSPE, ASPAE, APPES, APEG, ISPAE, CSPEM and ESPGHAN*, and included endocrinologists and experts from the fields of nutrition, paediatrics, public health, epidemiology and health economics.

The consensus group established definitions for rickets, vitamin D and calcium deficiency; intakes of vitamin D and calcium required for prevention and treatment of rickets and osteomalacia, including in women of child-bearing age, pregnancy and lactation; and identification of risk groups who benefit from screening and supplementation.

The group also developed a number of recommendations. Women of child-bearing age, particularly during pregnancy, should meet their recommended intakes of calcium and vitamin D. All infants should be supplemented with 400 IU/day of vitamin D until 12 months of age, and calcium-rich foods should be introduced no later than 6 months. Food fortification with vitamin D is recommended to increase average population intakes to 400 IU/day, a level that would eradicate rickets and osteomalacia.

Nutritional rickets, a fully preventable disorder, is on the rise worldwide and should be as unacceptable to public health as polio or measles, and thus regarded as a global epidemic. The consensus group advocates eradication of rickets and osteomalacia through implementation of international vitamin D supplementation and food fortification programmes.

Members of the consensus group:


*PES, Pediatric Endocrine Society; SLEP, Sociedad Latinoamericana de Endocrinología Pediátrica; JSPE, Japanese Society for Pediatric Endocrinology; ASPAE, African Society for Paediatric and Adolescent Endocrinology; APPES, Asia Pacific Paediatric Endocrine Society; APEG, Australasian Paediatric Endocrine Group; ISPAE, Indian Society for Pediatric and Adolescent Endocrinology; CSPEM, Chinese Society of Pediatric Endocrinology and Metabolism; and ESPGHAN, European Society for Paediatric Gastroenterology Hepatology and Nutrition.

Accreditation and Syllabus Subcommittee

THE ESPE ACCREDITATION AND SYLLABUS SUBCOMMITTEE was established under the umbrella of the Education and Training Committee (Chair Jan Lebl) in 2011. Since then, it has been working to update the 1998 version of the ESPE Training Programme. The updated syllabus should revise, restructure and amend the current guidelines in the light of present practice and new developments, should evaluate the feasibility of the current tutorial system approach in view of national differences in paediatric training, and should also focus on minimum but obligatory requirements.

After liaising with several colleagues from EU countries, obtaining feedback using a questionnaire and advertisement through the website, ESPE Newsletter, e-alerts etc., the Subcommittee worked on updating the training syllabus in paediatric endocrinology based on the recommendations of the European Academy of Paediatrics (EAP) and the European Board of Paediatrics, to present it to the ESPE Council. The final version was prepared in 2013, put on the ESPE website for feedback and evaluation, presented at the last ESPE meeting in 2013 and put forward to EAP for approval.

Finally, the revised ESPE Training Programme was approved at the last EAP Meeting in May 2014 in the Tertiary Care Working Group and in the General Assembly of EAP. The latest version has been published at www.euroespe.org/education/training/ESPE-Syllabus_May-2013.pdf.

Following this approval, more important issues will come onto the agenda, such as methods to bring this training programme into practice, recognition and accreditation of the training centres and certification of the trainees. The Accreditation and Syllabus Subcommittee will work on these items before presenting them to members and colleagues for finalisation.

Current members of the Subcommittee are: Feyza Darendeliler (Turkey; Chair), Stefano Cianfarani (Italy), Sten Drop (The Netherlands), Jan Lebl (Czech Republic), Wilma Oostdijk (The Netherlands), Giorgio Radetti (Italy), Stefan Riedl (Austria), Lars Sävedahl (Sweden).
In anticipation of ESPE 2014...

Some of the key speakers give a flavour of what you can expect to enjoy at ESPE 2014 this September in Dublin.

Closed-loop system: dream or reality?

Good glycaemic control is crucial to prevent diabetes-related complications as well as hypoglycaemic episodes, seizure, coma and death. The Diabetes wiREless Artificial pancreas consorTiU (DREAM) was established by three diabetes centres in Slovenia, Germany and Israel, with the aim of reducing the risk of hypoglycaemia while improving blood glucose control and reducing patients’ burden of diabetes management by using the MD-Logic system. This is a wireless fully automated closed-loop system based on a fuzzy-logic theory algorithm, with learning capability, personalised system settings and safety alert module.

Since October 2010, in silico studies using the US Food and Drug Administration-approved UVa (University of Virginia) simulator (n=300 virtual patients) and clinical studies have been conducted by the three centres, with more than 200 children, adolescents and adults with type 1 diabetes. After the successful conclusion of first feasibility in-hospital studies, a set of prospective randomised controlled, multicentre, multinational, cross-over studies was conducted in hospitals, at diabetes camps and at patients’ homes. We first used the GlucoSitterTM as a solution for nocturnal blood glucose control, and recently a full 24-hour closed-loop system was tested successfully at patients’ homes.

Results showed the safety and efficacy of the MD-Logic system both overnight and during the day. It achieved significantly less hypoglycaemia and tighter overnight glucose control than sensor augmented pump therapy. The MD-Logic system may be safely integrated into lives of people with diabetes. The DREAM consortium is now evaluating the system over a longer study period at patients’ homes.

Moshe Phillip
Schneider Children’s Medical Center of Israel, Petah Tikva, Israel

Novel therapies for congenital hyperinsulinism

Congenital hyperinsulinism (CHI) refers to a group of conditions characterised by dysregulated insulin secretion from pancreatic beta-cells. The inappropriate insulin secretion leads to severe hyperinsulinaemic hypoglycaemia.

At a histological level, there are two major subtypes of CHI: focal and diffuse. The management of focal CHI has been revolutionised by the development of 18F-DOPA-PeT/CT scanning and laparoscopic surgery. Correct pre-operative localisation by 18F-DOPA-PeT/CT scanning and complete surgical removal of the focal lesion can cure the patient of hypoglycaemia.

In contrast, the management of diffuse disease is complex and highly challenging for paediatric endocrinologists. Until recently, a near-total pancreatectomy was the only option for those with diffuse CHI who did not respond to conventional medical therapies (such as diazoxide and octreotide). A near-total pancreatectomy inevitably leads to post-pancreatectomy diabetes mellitus and pancreatic exocrine insufficiency.

Thus there is an urgent need to develop novel therapies to avoid this procedure. Current research involves using (a) chaperone agents (such as sulphphonylureas) to recruit defective KATP channels to the beta-cell membrane surface, (b) glucagon-like peptide-1 receptor antagonists to lower CAMP levels in defective beta-cells, (c) long-acting octreotide formulations (such as lanreotide), or more recently (d) mTOR inhibitor drugs (such as sirolimus) in patients with severe diffuse disease.

Khalid Hussain
University College London, UK

Childhood obesity - new treatments and the imperative for prevention

The primary causes of the complex obesity pandemic are clear. Energy intake has shifted to high sugar, high salt and high fat foods and drink, pedalled to our children by a food and drinks industry supported by regulatory inaction. Combined with this, physical activity levels have dropped and physical inactivity levels have soared.

We know that childhood obesity is three times more common and more extreme in lower socio-economic groups. We are learning that the genes for diabetes and heart disease are switching on, and the genes for cancer defence are switching off, at as early as the age of 6, and in direct proportion to the degree of obesity. These facts, combined with the low self-image and esteem experienced by obese children, must drive the impetus for aggressive preventive measures to be more widely identified and adopted.

The scale of rise in childhood obesity demands that treatments be improved. Current conservative weight management interventions can deliver up to 10% weight loss, with bariatric surgery delivering 30% weight loss – and experience in children is increasing. Safer, more effective alternatives are needed. The recent recognition and understanding of how the immune system regulates body weight dynamically has opened up new possibilities for therapies. Currently oral bile salt preparations, analogues of glucagon-like peptide-1, fibroblast growth factor-21 and implantable upper GI stents are being studied, and all would be potentially suitable in children.

Donal O’Shea
St Vincent’s University Hospital and University College Dublin, Ireland

See www.espe2014.org for further details
The McCune-Albright syndrome (MAS) can be a disease of striking complexity, the management of which can be challenging. However, an understanding of the physiologic consequences of the underlying molecular and developmental biology makes the evaluation and treatment of this disease relatively straightforward.

MAS arises from activating mutations in the ubiquitously expressed cAMP-signalling protein, Gsα. The mutations occur very early in development, prior to gastrulation. The timing and location of the mutational event dictate the ‘map’ of affected tissues. As such, a thorough phenotyping at presentation allows for the identification of all affected and (just as important) unaffected tissues to track over a patient’s lifetime.

Identifying affected and unaffected tissues, and understanding the effects of cAMP signalling in a given tissue, explain the clinical presentation, help determine treatment, and allow for accurate prognosis (see figure). Each patient is different, and the array of tissues affected ranges from few to many. In complex cases, care often involves the co-ordinated efforts of multiple subspecialists. Patients suffer and parents are often frustrated by the fragmentation of care that can occur.

Managing McCune-Albright syndrome

The most common form of congenital adrenal hyperplasia (CAH) is classic 21-hydroxylase deficiency, characterised by a defect in cortisol and aldosterone secretion, impaired development and function of the adrenal medulla, and adrenal hyperandrogenism.

Treatment aims to provide adequate glucocorticoid and, when necessary, mineralocorticoid substitution, to prevent adrenal crises, and to suppress the excess secretion of androgens and steroid precursors from the adrenal cortex. However, current formulations of hydrocortisone are unable to simulate physiological cortisol secretion, and patients are at risk of developing iatrogenic Cushing’s syndrome and hyperandrogenism in tandem.

Treatment optimisation has been attempted using thrice-daily dosing, which still fails to simulate the normal diurnal rhythm of cortisol secretion and results in temporary over- or under-replacement. Proof-of-concept studies using hydrocortisone infusions predict improvement in biochemical control and quality of life. The use of delayed- and extended-release hydrocortisone formulations offers the prospect of more physiological cortisol replacement.

Recent formulations use a scalable technology based on multiparticulates. The design configuration comprises an inert microcrystalline core coated with a drug layer and then further coated with polymeric layers that modify drug release. Following screening of several multiparticulate formulations, in vitro and in vivo, an optimal formulation has been chosen, which reproduces the overnight rise in cortisol. When given as a twice-daily regimen, this has provided cortisol exposure similar to that seen in physiological cortisol concentrations in a healthy reference population and also in dexamethasone-suppressed healthy volunteers after a single dose of 30mg hydrocortisone.

Other therapeutic alternatives that might be used in conjunction with substitution therapy include gonadotrophin-releasing hormone analogues, anti-androgens and aromatase inhibitors. Many of these agents still require further evaluation in patients with the classic form of the disease.

Advances in therapy for CAH

A fairly comprehensive, evidenced-based literature exists to guide physicians. A concise distillation of this literature will be reviewed in this session, to equip the paediatric endocrinologist with the tools to understand MAS, and to co-ordinate and direct care of this often challenging and complex disease.

Michael Collins
Skeletal Clinical Studies Unit, NIH, Bethesda, MD, USA

Evangelia Charmandari
Aghia Sophia Children’s Hospital, Athens, Greece

Follow ESPE online...

Keep an eye on the ESPE news alerts, Facebook, Twitter and www.espe2014.org for all updates relating to the ESPE annual meeting.

If tweeting about ESPE 2014, please use the hashtag #espe2014 so that others can follow the tweets about the meeting.
AN INTERVIEW WITH...

Jan Lebl

Past ESPE President, Chair of the Education and Training Committee and ESPE Council Member Jan Lebl (Prague, Czech Republic) gives us an insight into why ESPE means so much to him, and how the Society can assist and inspire new members.

How would you describe your association with ESPE?

For me, ESPE is truly a matter of the heart. After the fall of the ‘iron Curtain’ 25 years ago, which had split Europe for two generations, it was ESPE who opened the door for us, the new incomers from Central and Eastern Europe. ESPE developed training programmes such as the Winter School, to overcome the gap in medical understanding between the ‘West’ and ‘East’ of Europe. This formed the roots of ESPE’s continuing efforts to spread medical knowledge and skills in parts of the world that were underprivileged in the past and have enthusiastic doctors ready to learn.

Tell us about your roles in clinical work and research?

I originally trained as a clinician, but I understood that paediatric endocrinology requires both clinical work and research. It may simply be that endocrinology is the most ‘translational’ of all medical specialties. Currently, we run our own labs which translate clinical experience to the bench and vice versa. The daily discussions among members of both teams (some of them sharing clinical and lab duties) stimulate the brain and the heart, and benefit the patients.

How does ESPE push the boundaries in learning and research in paediatric endocrinology?

Within the past two decades, ESPE greatly expanded the boundaries of learning, training and research in paediatric endocrinology, diabetes and obesity. In collaboration with the sister societies, training is now also becoming available in Africa, the Middle East, Central Asia and the Caucasus, with the supervision and active participation of experts from the entire region. In addition, ESPE teachers take part at training courses in India, China and the Asia-Pacific area. In Europe, teaching courses at different levels cover the needs of those who require training in clinical practice, translational research and basic research.

What advice would you give to new ESPE members?

Take the opportunity to participate in some of the ESPE education and training activities, according to your area of interest and country of residence. To get the best overview of what is available in the forthcoming year, attend the special Education and Training Session at the annual ESPE meeting in Dublin (Thursday 18 September, 09.00–11.00).

5th ASPAE Conference

Dar es Salaam, Tanzania, 14–16 May 2014

THE THEME FOR THIS YEAR’S CONFERENCE of the African Society for Paediatrics and Adolescent Endocrinology (ASPAE) was ‘Overcoming challenges in childhood diabetes and other endocrine disorders in an African setting’. There were 63 delegates from at least 14 countries, across Africa and further afield.

The conference was opened by the Chief Medical Officer from the Tanzanian Ministry of Health and Social Welfare, Donan Mmbando. In his opening remarks, Dr Mmbando commented that, for the last two decades, most of the developing world (including sub-Saharan Africa) has mobilised resources to fight communicable diseases, paying little attention to non-communicable diseases, including diabetes and other endocrine disorders.

He cited recent statistics from bodies such as the International Diabetes Federation, which reveal that non-communicable diseases are on the rise in Africa and that, without intervention, they will reach epidemic proportions by 2035. To address their prevention and control, Dr Mmbando said his government has been working with groups such as the Tanzania Diabetes Association and Changing Diabetes in Children. They have set up diabetes clinics and trained healthcare workers in diabetes management in over 35 centres across Tanzania. Anti-diabetic medications including insulin and glucose monitoring equipment are provided free of charge for children.

The scientific programme covered almost all areas of contemporary interest, with an emphasis on the most prevalent disorders in Africa: diabetes, rickets and congenital hypothyroidism. Some presentations touched on the field of rare diseases, which was very promising for future development. The participants – mostly trained at the Paediatric Endocrinology Training Centre for Africa (PETCA) – confidently presented their own work. Other participants were general paediatricians who benefited from coverage of areas outside their training curriculum, strengthening their interest in a career in paediatric endocrinology.

For former ESPE PETCA tutors and representatives from the International Society for Pediatric and Adolescent Diabetes/Australasia Paediatric Endocrine Group, it was inspiring to see how former students had developed professionally in recent years! The access of African children to competent endocrine care has surely been enhanced. It is of no doubt that with so much support between themselves, as well as from ESPE and other professional societies, ASPAE will succeed.

Edna Majaliwa, Kandi Muze, Dipesalema Joel and Violeta Iotova
ESPE Visiting Scholarship

THE ESPE VISITING SCHOLARSHIP offers financial support to members of the Society or to their collaborators/team members. This support can be used to gather information and experience regarding a specific research issue OR on a laboratory technique in the field of paediatric endocrinology. ESPE is very grateful to Pfizer for supporting this very important resource in recent years.

It is especially valuable to early stage investigators who are eager to spend a short period of up to 6 weeks abroad in order to improve their skills in research by developing new research methods. The Scholarship may be used to transfer knowledge and techniques to the home institution or to connect the researcher with a scientific unit for further collaboration using other funding mechanisms. For the Visiting Scholarship, the funding needed for travel and accommodation must be specified, and will be reimbursed up to €2500. In 2013, nine proposals were received and five approved.

The application process is straightforward, and applications may be submitted four times each year, on 31 January, 30 April, 31 July and 31 October (see www.eurospe.org/awards/awards_visiting_scholar.html for further details).

The applications are evaluated by the Visiting Scholarship Committee, currently comprising Agnes Linglart (Paris, France), Vallo Tillmann (Tartu, Estonia), and Olaf Hiort (Lübeck, Germany; Chair).

Olaf Hiort

Hellenic Society of Pediatric and Adolescent Endocrinology

EEnEE, the Hellenic Society of Pediatric and Adolescent Endocrinology, is a ‘young society’, founded in 1995 and currently numbering 51 members, led by President George P Chrousos.

The EEnEE is not organised around multisite collaborative working groups, unlike many other national societies, but concentrates on paediatric endocrinology training in the Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics at the University of Athens, and in Athens’ Children’s Hospital Aghia Sophia, as well as in other national centres.

Similarly, the performance of many special endocrine studies is centralised at the Choremeion Research Laboratory (University of Athens), at the Biomedical Research Foundation of the Academy of Athens and at other university, public health service and private laboratories.

EEnEE holds an annual meeting. The national accreditation in paediatric endocrinology is under development, as is the elaboration of national guidelines following the ESPE syllabus.

For further information contact George P Chrousos, EEnEE President, at e.e.p.e.endo@gmail.com.

Auxology: Studying Human Health and Development

Michael Hermanussen (Editor & Lead Author), Schweizerbart, Germany, 2013, 324 pp, €39.90, ISBN 978-3-510-65278-5

WHO KNOWS WHAT AUXOLOGY MEANS? If you are reading this review as a paediatric endocrinologist then you probably do. But I bet you think of textbooks on auxology as thick and dull, full of incomprehensible formulae and tables, and best employed as a doorstop.

Well this is so completely different that perhaps it should have been called ‘Everything sexy about growth’ to liven up interest! So, why is it different? Well it has lots of bright, easy to understand diagrams, photos, funny cartoons, and imaginary letters and conversations to break up the text, which is in bite-size chunks, and full of coloured words and bold phrases to aid skim-readers.

Although sometimes verging on being light on facts, you can generally get all the information you need and be pointed to the original sources in a huge bibliography if you want more detail. Each topic is covered by a two-page spread which opens in front of you, and one section leads on from another. All the areas you expect to be covered are there, fully updated. Other new ones, like face shape analysis, are completely fascinating. The many bright and clear diagrams make excellent teaching aids and make the book fun to read.

For new readers there is short section on growth statistics for bunnies – easy to follow, but unfortunately parametric and regression analysis gets six pages of unadulterated formulae and text. It’s old fashioned auxology, but this is the only transgression. It is good as bedtime reading and a clinic manual with many useful tables and references.

So you think you know all about growth as a paediatrician then? I think you would find some useful new knowledge on every page, so it is a recommended read. Auxology is back in fashion!

Gary Butler, London, UK
Future meetings

See www.eurospe.org/meetings for details of all future meetings

Other Events

ESPE Summer School 2014
15–17 September 2014
BARRETSTOWN CASTLE, IRELAND

1st ESPE Caucasus & Central Asia School
24–30 October 2014
ALMATY, KAZAKHSTAN

ESPE-ASPED School
3–8 November 2014
ABU DHABI, UAE

ESPE Maghreb Project
12–16 November 2014
MOROCCO

ESPE Newsletter

© 2014 The European Society for Paediatric Endocrinology
The views expressed by the contributors are not necessarily those of ESPE

Editor: Professor Feyza Darendeliler
Istanbul Tip Fakultesi
Cocuk Sagligi Ve Hastaliklari
Anab Dali, Capa
Istanbul, TR-34390, Turkey
Email: feyzad@istanbul.edu.tr

Designed by: Sublime Creative

Published by: Bioscientifica Ltd
Euro House, 22 Apex Court, Woodlands
Bradley Stoke, Bristol BS32 4JT, UK

www.bioscientifica.com
Bioscientifica is a subsidiary of the Society for Endocrinology

ESPE Office

The ESPE Office is managed by Bioscientifica Ltd, headed by Managing Director Leon Heward-Mills.

Bioscientifica’s Associations Managers (Hannah Bonnell and Joanne Fox-Evans) oversee the day-to-day relationship with ESPE, liaising with the ESPE Council and committee members as well as being the main point of contact for ESPE enquiries. They undertake projects requested by the Secretary General, providing him with assistance and attending ESPE Council and committee meetings. Tracey-Leigh Meadowcroft handles membership renewals and payments and deals with subscriptions to Hormone Research in Paediatrics.

Bioscientifica also manages the Corporate Liaison Board which deals with industry sponsors, and is also responsible for publication of the ESPE Newsletter and monthly news alerts.

ESPE, Bioscientifica Ltd, Euro House, 22 Apex Court, Woodlands, Bradley Stoke, Bristol BS32 4JT, UK
Tel: +44 (0)1454 642246 Fax: +44 (0)1454 642222;
Email: espe@eurospe.org

Deadlines

Please note these fast-approaching deadline dates and submit your applications as soon as possible.

ESPE 2014 standard registration 23 Jul 2014
ESPE Visiting Scholarship applications 31 Jul 2014
ESPE Winter School applications 25 Oct 2014
ESPE Visiting Scholarship applications 31 Oct 2014
ESPE Andrea Prader Award nominations 10 Dec 2014
ESPE Research Award nominations 10 Dec 2014
ESPE Young Investigator Award nominations 10 Dec 2014
ESPE Outstanding Clinician Award nominations 10 Dec 2014
ESPE International Award nominations 10 Dec 2014

See the ESPE website www.eurospe.org for further details and the application process

Secretary General:
Professor Lars Sävendahl, MD, PhD
Academic Chair, Division of Paediatrics
Karolinska University Hospital,
Q2:08, SE-171 76 Stockholm, Sweden
Tel: +46 (0)8 51772369
Fax: +46 (0)8 51775128
Email: lars.savendahl@ki.se

ESPE website: www.eurospe.org